Hepatitis C Drug Market Size, Share, Growth Report 2030

Hepatitis C Drug Market

Hepatitis C Drug Market by End-User (Hospitals, Private labs, Physician offices, Public health labs, and Blood Bank): Global Industry Perspective, Comprehensive Analysis and Forecast, 2020 – 2028

Published Date: 26-Jul-2021 Category: Pharmaceutical Report Format : PDF Pages: 150 Report Code: ZMR-1326 Status : Published

The global Hepatitis C Drug market accounted for USD 20.5 Billion in 2020 and is expected to reach USD 69.1 Billion by 2028, growing at a CAGR of around 16.3% between 2021 and 2028.

Hepatitis C Drug Market: Overview 

The global Hepatitis C Drug market accounted for USD 20.5 Billion in 2020 and is expected to reach USD 69.1 Billion by 2028, growing at a CAGR of around 16.3% between 2021 and 2028.    

Hepatitis is inflammation of the liver characterized by yellowed eyes and skin due to bilirubin, flu-like symptoms which include nausea, vomiting headaches, poor appetite, joint pain, and clay-colored stools.

Hepatitis C is a significant public health concern that affected more than 400.2 Million patients globally in 2019. Even more alarming, only 0.4 Million were treated per year, showing the need for increased screening and timely diagnosis.

The partnerships and mergers and acquisitions of players in the Hepatitis C Drug market are also set to propel the market growth. For example, in April 2019, U.S. FDA announced the approval of Mavyret by AbbVie as the first-ever treatment approved for pediatric patients of all genotypes of hepatitis C.

COVID-19 Impact Analysis:

The lockdowns imposed by various countries to contain the spread of Covid-19 has impacted the global operations and supply chain which had negative consequences on the Hepatitis C Drug market as global sales declined. As healthcare professionals increasingly direct their resources towards caring for coronavirus-infected patients, other health issues are being relegated to the back seat. The players in the industry have temporarily suspended the production of Hepatitis C drugs in order to cater to coronavirus patients.

The significant decrease in the global Hepatitis C Drug market size in 2020 is estimated on the basis of the COVID-19 outbreak and its negative impact on the economies and industries across the globe. Various scenarios have been analyzed on the basis of inputs from various secondary sources and the current data available about the situation.   

To know more about this sample, request a free sample copy.

Growth Factors

The global hepatitis C drug market was likely to see development in the near future owing to an increase in the occurrence of HCV all over the world. In addition to this, lack of awareness is believed as a major fostering factor that promotes the growth of the hepatitis C drug market. Moreover, many lifestyle-associated factors, such as transferring of body fluid, unsafe sex, and having multiple sex partners are likely to propel the development of the hepatitis C drug market. On the other hand, lack of information and awareness about HCV, threat-related to the development & regulation of drugs, and treatment costs might hinder the development of the hepatitis C drug market.

Nevertheless, new efficient treatments are likely to bring growth opportunities to the hepatitis C market in the foreseeable future. For example, in April 2018, a nonprofit organization made a new hepatitis C medication that is just as effective as those made by other drug giants. This is supposed to bolster the development of the hepatitis C drug market.

Report Scope:  

Report Attribute Details
Base Year 2022
Historic Years 2018 - 2022
Forecast Years 2023 - 2030
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2023 to 2030
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Segment Analysis Preview  

The hepatitis C drug market is divided based on end-users into five types such as private labs, hospitals, public health labs, physician offices, and blood banks. These sectors are the major end-users of the global hepatitis C drug market. In terms of income, hospitals were the dominating end-user recently and the same is anticipated to be the fastest and biggest developing sector in the hepatitis C drug market during the forecast period.

Regional Preview:

North America was the dominating market for hepatitis C drug market in terms of income owing to the broad accessibility of hospitals. Moreover, lifestyle-associated factors such as unprotected sex and having multiple sex partners have become very ordinary in European nations and North America. Furthermore, hepatitis C drug has huge growth avenues in emerging regions such as Latin America and the Asia Pacific due to government initiatives, the rising number of patients suffering from HCV, and healthcare infrastructure.

Key Market Players & Competitive Landscape

The major players operating the Hepatitis C Drug market are Merck & Co, Kenilworth, Roche, Basel GlaxoSmith, Gilead Sciences, AbbVie, Johnson & Johnson, and Bristol-Myers Squibb.

To know more about this sample, Request For Customization.

The global Hepatitis C Drug market is segmented as follows:  

By End-User

  • Hospitals
  • Private labs
  • Physician offices
  • Public health labs
  • Blood Bank

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

Methodology

Free Analysis

FrequentlyAsked Questions

The global Hepatitis C Drug Market was valued at USD 20.5 Billion in 2020.

The global Hepatitis C Drug Market is expected to reach USD 69.1 Billion by 2028, growing at a CAGR of 16.3% between 2021 to 2028.

Some of the key factors driving the global Hepatitis C Drug Market growth are lifestyle-associated factors, such as transferring of body fluid, unsafe sex, and having multiple sex partners.

North America was the dominating market for hepatitis C drug market in terms of income owing to the broad accessibility of hospitals. Moreover, lifestyle-associated factors such as unprotected sex and having multiple sex partners have become very ordinary in European nations and North America.

Some of the major players of global Hepatitis C Drug market are Merck & Co, Kenilworth, Roche, Basel GlaxoSmith, Gilead Sciences, AbbVie, Johnson & Johnson and Bristol-Myers Squibb.

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed